

NOVO NORDISK A S  
Form 6-K  
July 07, 2014  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

July 7, 2014

---

NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

Novo Allé  
DK- 2880, Bagsvaerd  
Denmark  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 7 July 2014 – On 1 May 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

## Edgar Filing: NOVO NORDISK A S - Form 6-K

Under the programme initiated 1 May 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 1 May 2014 to 5 August 2014.

Since the announcement as of 1 July 2014, the following transactions have been made under the programme:

|                                 | Number of<br>B shares | Average<br>purchase price | Transaction<br>value, DKK |
|---------------------------------|-----------------------|---------------------------|---------------------------|
| Accumulated, last announcement  | 9,786,000             |                           | 2,354,700,476             |
| 1 July 2014                     | 230,000               | 249.66                    | 57,422,191                |
| 2 July 2014                     | 275,000               | 253.00                    | 69,573,818                |
| 3 July 2014                     | 240,000               | 253.67                    | 60,880,248                |
| 4 July 2014                     | 210,000               | 253.40                    | 53,213,643                |
| Accumulated under the programme | 10,741,000            |                           | 2,595,790,375             |

With the transactions stated above, Novo Nordisk owns a total of 29,178,014 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 4 July 2014, Novo Nordisk has repurchased a total of 26,174,995 B shares equal to a transaction value of DKK 6,300,478,512.

---

